An Introduction to COVID-19
On 11 March 2020, the World Health Organization declared COVID-19 a global pandemic. The impact on the medical community has been huge, not only on the front line of medical care but also for those navigating patient treatment during this unprecedented situation.
The touchIMMUNOLOGY expert faculty have been sharing their experiences and advice during this challenging time through video interviews and short articles.
Alessio Cortellini, ESMO Immuno-Oncology 2022: Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer
A joint analysis of patients receiving immune checkpoint inhibitor therapy was conducted using the OnCovid (NCT04393974) and ESMO CoCARE registries, this assessed SARS-CoV-2 outcomes in vaccinated and unvaccinated patients with cancer and whether prior immune-related adverse events affected these outcomes. In this touchIMMUNOLOGY interview, we spoke with Dr Alessio Cortellini (Fondazione Policlinico Universitario Campus Bio-Medico, […]
SARS-CoV-2 Vaccine Immunogenicity in Patients with Autoimmune Inflammatory Rheumatic Diseases
touchREVIEWS in RMD. 2022;1(2):38–9
While the efficacy of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in preventing serious disease is well documented, studies are now emerging in immunosuppressed individuals. Among these are studies on the vaccination response in individuals with autoimmune inflammatory rheumatic diseases who take immunosuppressant therapies. In this expert interview, Dr Victoria Furer from the Tel Aviv […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Giovanni Marasco, UEG Week 2022: Findings from the GI-COVID-19 Study
The GI-COVID-19 study (ClinicalTrials.gov NCT04691895) was a prospective, multicenter, controlled study investigating the prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19. We were delighted to talk with Dr. Giovanni Marasco (Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy) to discuss the aims, methodology and findings in terms of prevalence of GI symptoms in patients with COVID-19 […]
James Alexander, UEG Week 2022: Antibody and T-cell Response to the Third COVID-19 Vaccine Dose in Immunosuppressed Patients with Inflammatory Bowel Disease
The VIP study was a multicentre, prospective, case-control study, investigating whether immunosuppressive treatments reduced antibody and T-cell responses in patients with inflammatory bowel disease (IBD) after a third COVID-19 vaccine dose. In this touchIMMUNOLOGY interview, we speak with Dr. James Alexander (Imperial College London, London, UK) to discuss the aims, methodology and findings from the […]
Stavros Dimitriadis, EASL ILC 2022: Immune responses to fourth COVID-19 vaccination in liver transplant recipients and patients with autoimmune hepatitis
In some countries, patients considered vulnerable have received 3rd/4th COVID-19 vaccine doses (V3/V4). This study, presented by Stavros Dimitriadis (University of Oxford, Oxford, UK), explores the immune response to V4 in a mixed disease cohort of immunosuppressed patients including liver transplant recipients and patients with autoimmune hepatitis. This study also focused on individuals with absent […]
James Alexander, ECCO-IBD 2022: COVID-19 Vaccination in Patients with IBD on Immunosuppressants
We caught up with Dr James Alexander (Imperial College London, London, UK) to discuss the impact of immunosuppressant drugs on COVID-19 vaccine responses in patients with IBD. The abstract ‘COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab’ (Presentation no. OP21) was […]
Luis Ostrosky, ACR 2021: Therapeutic Options for COVID-19
TouchIMMUNOLOGY were delighted to talk with Professor Luis Ostrosky (Infectious diseases, UTHealth, Houston, TX, USA) around his presentation titled ‘COVID-19: Update on Therapeutics‘, which was presented at the ACR Convergence, 3-9 November 2021. This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College […]
David Pesqué, EADV 2021: mRNA COVID-19 Vaccine Skin Reactions
It was an absolute pleasure to speak with Dr David Pesqué (Universitat Autònoma de Barcelona, Barcelona, Spain) about his study investigating the skin reactions seen in response to mRNA COVID-19 vaccines. His presentation entitled ‘Clinical characterization of skin reactions due to mRNA COVID-19 vaccines at a tertiary-level hospital: a descriptive study’ was given at the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!